CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia ...

Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...

PanCAN PurpleStride Chicago welcomes first time Premier Sponsor Endevica Bio, who is dedicated to advancing novel treatments ...

A majority of people with advanced cancers endure cachexia, a muscle-, fat-, and organ-wasting condition that is currently ...

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

Curanex Pharmaceuticals Inc. CURX on Monday said that a recent patient case study may reinforce its strategic push into cancer cachexia, a severe wasting condition tied to advanced cancers with ...

NORTHBROOK, Ill.--(BUSINESS WIRE)--Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, has closed a $10 million Series B funding. The ...